DOCSLIB.ORG

Eurofins Forensic Services Limited

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Eurofins Forensic Services Limited Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Staines-upon-Thames, TW18 3HR, UK Eurofins Forensic Services Limited Issue No: 064 Issue date: 21 September 2021 Queens Road Contact: Mr Martin Hanly Teddington E-Mail: [email protected] Middlesex 10007 TW11 0LY Accredited to ISO/IEC 17025:2017 Testing performed by the Organisation at the locations specified below Locations covered by the organisation and their relevant activities Laboratory locations: Location details Activity Location code Address Mr Martin Hanly Toxicology (Workplace) Teddington Queens Road Forensic Analysis Teddington Email: [email protected] Medical/Veterinary Middlesex Website: www.eurofins.com TW11 0LY Address Mr Martin Hanly Forensic Analysis Culham E4 Culham Science Centre Abingdon Email: [email protected] Oxfordshire Website: www.eurofins.com OX14 3ED Address Mr Martin Hanly Forensic Analysis Birchwood Park Darwin House Medical/Veterinary Faraday Street Email: [email protected] Birchwood Park Website: www.eurofins.com Risley Cheshire WA3 6FW Address Mr Martin Hanly Forensic Analysis Leeds Royal Armouries Armouries Drive Email: [email protected] Leeds Website: www.eurofins.com LS10 1LT Address Mr Martin Hanly Forensic Analysis Tamworth Building 3 Swiss Lodge Drive Email: [email protected] Drayton Manor Business Park Website: www.eurofins.com Tamworth Staffordshire B78 3GL Assessment Manager: DP Page 1 of 54 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Chertsey Lane, Sta ine s -u po n - Thames, TW18 3HR, UK Eurofins Forensic Services Limited 10007 Issue No: 064 Issue date: 21 September 2021 Accredited to ISO/IEC 17025:2017 Testing performed by the Organisation at the locations specified Location details Activity Location code Address Mr Martin Hanly Forensic Analysis Wakefield Sir Alec Jeffreys Building Peel Avenue Email: [email protected] Calder Park Website: www.eurofins.com Wakefield WF2 7UA Address Mr Martin Hanly Forensic Analysis Lambeth 109 Lambeth Road London Email: [email protected] SE1 7LP Website: www.eurofins.com Address Mr Martin Hanly Forensic Analysis Heathrow 1 Dukes Green Avenue Feltham Email: [email protected] TW14 0LR Website: www.eurofins.com Address Mr Martin Hanly Birmingham 22 Gas Street, Birmingham Email: [email protected] B1 2JT Website: www.eurofins.com Customers’ sites or premises Sampling for COVID-19 testing purposes The customer’s sites or premises must be suitable for the sampling undertaken and will be subject of contract review arrangements between the provider and the customer Assessment Manager: DP Page 2 of 54 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Cher tsey Lane, Staines -u po n - Thames, TW18 3HR, UK Eurofins Forensic Services Limited 10007 Issue No: 063 Issue date: 14 September 2021 Accredited to ISO/IEC 17025:2017 Testing performed by the Organisation at the locations specified DETAIL OF ACCREDITATION Materials/Products tested Type of test/Properties Standard specifications/ Location measured/Range of Equipment/Techniques used Code measurement HUMAN BODY FLUIDS Virology Testing Nasopharyngeal swabs (throat Detection of SARS-CoV-2 (COVID- Documented In-House Birchwood and nasal) (dry swabs and 19) virus specific gene sequences Methods including DHSC Park swabs in Viral Transport (N1 gene and E gene) for requirements for private Media (VTM)) subsequent clinical interpretation at providers of COVID-19 testing private or NHS facilities by - Extraction using GSD medically qualified personnel to ViroBOAR SARS include testing for the following CoV-2 RNA detection purposes: kit and Hamilton Starlet, TANBead General Population Maelstrom 9600 or Detection of SARS-CoV-2 (COVID- KingFisher Flex 19) virus RNA using molecular robotic systems. methods or antigen POCT - Detection using the Test to Release 5 Day GSD ViroBOAR Detection of SARS-CoV-2 (COVID- SARS-CoV-2 RNA 19) virus RNA using molecular detection kit, Nayo 96 methods for qPCR set up and Agilent Aria Dx Real Detection of SARS-CoV-2 RNA Time PCR system (COVID-19) virus specific gene sequences using the GSD ViroBOAR SARS-CoV-2 RNA - Extraction using GSD Teddington detection kit. Target: Two specific ViroBOAR SARS- regions of the SARS-CoV-2 N CoV-2 RNA detection gene kit and TANBead Maelstrom 9600 For General Population testing and Kingfisher Flex and Test to release (TTR) and day extraction platforms 2 and 8 international arrivals (IA) plus Nayo 96 and Multiflo FX pipetting With clinical interpretation by Platforms medically qualified personnel - Detection using the GSD ViroBOAR SARS-CoV-2 RNA detection kit, ABI 7500 FAST, QuantStudio 5 and Aglient AriaMx platforms Assessment Manager: DP Page 3 of 54 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Cher tsey Lane, Staines -u po n - Thames, TW18 3HR, UK Eurofins Forensic Services Limited 10007 Issue No: 063 Issue date: 14 September 2021 Accredited to ISO/IEC 17025:2017 Testing performed by the Organisation at the locations specified Materials/Products tested Type of test/Properties Standard specifications/ Location measured/Range of Equipment/Techniques used Code measurement HUMAN BODY FLUIDS Virology Testing (cont’d) (cont’d) Nasopharyngeal (Nose) Sampling with subsequent testing In-house method for COVID- Swab at a laboratory accredited to ISO 19 sampling for testing 15189:2012 or ISO/IEC purposes 17025:2017 and who is listed on the DHSC Approved List for the testing performed. For: General Population Detection of SARS-CoV-2 (COVID- 19) virus RNA using molecular methods or antigen POCT Test to Release 5 Day Detection of SARS-CoV-2 (COVID-19) virus RNA using molecular methods Test to Release 2 and 8 Day Detection of SARS-CoV-2 (COVID-19) virus RNA using molecular methods Forensic Testing The organisation has Teddington demonstrated adherence to Tamworth the relevant requirements of Culham the Forensic Science Birchwood Regulators Code of Practice Park and Conduct in relation to their Leeds Forensic Activities Wakefield Lambeth Heathrow Assessment Manager: DP Page 4 of 54 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Cher tsey Lane, Staines -u po n - Thames, TW18 3HR, UK Eurofins Forensic Services Limited 10007 Issue No: 063 Issue date: 14 September 2021 Accredited to ISO/IEC 17025:2017 Testing performed by the Organisation at the locations specified Materials/Products tested Type of test/Properties Standard specifications/ Location measured/Range of Equipment/Techniques used Code measurement BODY FLUIDS and TISSUES Forensic Testing Blood - Stains Short Tandem Repeat (STR) DNA Documented In-House Birchwood Semen profiling for forensic analysis of: Methods using Park - Whole - Crime Scene Samples manual/automated extraction - Azoospermic meeting the requirements - Auto-Lys Saliva of the Custodian for the - Qiagen DNA - Stains Purpose of Supply to the Investigator STAR - Swabs National DNA Database DART Manual Auto- Hair - Environmental Samples Lys Cellular Material - Ammunition and heavy non-porous objects Swabs Body Tissue Short Tandem Repeat (STR) Documented In-House Birchwood - Bone DNA profiling for forensic analysis Methods using Park - Teeth of: manual/automated extraction - Crime Scene Samples - Qiagen DNA meeting the requirements Investigator of the Custodian for the - Qiagen Maxi Kit Purpose of Supply to the - AutoLys National DNA Database Documented In-House Birchwood Method using automated Park quantification - Power Quant Documented In-House Birchwood Methods using automated Park amplification (PCR) and the following chemistry: - ESI 17 fast - Y23 Assessment Manager: DP Page 5 of 54 Schedule of Accreditation issued by United Kingdom Accreditation Service 2 Pine Trees, Cher tsey Lane, Staines -u po n - Thames, TW18 3HR, UK Eurofins Forensic Services Limited 10007 Issue No: 063 Issue date: 14 September 2021 Accredited to ISO/IEC 17025:2017 Testing performed by the Organisation at the locations specified Materials/Products tested Type of test/Properties Standard specifications/ Location measured/Range of Equipment/Techniques used Code measurement BODY FLUIDS and Forensic Analysis (cont’d) Documented In-House Birchwood TISSUES (cont’d) Method using Park - Electrophoresis - Applied Biosystems 3500 Genetic Analyser© Product of Conception Short Tandem Repeat (STR) Documented In-House Birchwood DNA profiling for forensic analysis method using Park of foetal tissue manual/automated extraction - Qiagen mini kit Documented in house Birchwood methods using Park manual/automated amplification: - ESI 17 fast - Y-23 Product of Conception Short Tandem Repeat (STR) Documented In-House Birchwood DNA profiling for forensic analysis Methods using Park of foetal tissue (cont’d) Electrophoresis - Applied Biosystems 3500 Genetic Analyser© Blood DNA Profiling: Documented In-House Birchwood - FTA cards Short Tandem Repeat (STR) Methods using Park Saliva DNA profiling for forensic analysis manual/automated extraction - FTA Cards of: - Qiagen DNA - Subject Samples Investigator - Qiagen Maxi Kit - AutoLys Documented In-House Birchwood Methods using Manual Park quantification - Power Quant Documented In-House Birchwood Methods using Manual Park amplification (PCR) and the following chemistry: - ESI 17 fast - Y23 - Promega Fusion 6C Assessment Manager: DP Page 6 of 54 Schedule of Accreditation issued by United Kingdom Accreditation
Load more

Recommended publications
  • WHO Expert Committee on Drug Dependence
    WHO Technical Report Series 1034 This report presents the recommendations of the forty-third Expert Committee on Drug Dependence (ECDD). The ECDD is responsible for the assessment of psychoactive substances for possible scheduling under the International Drug Control Conventions. The ECDD reviews the therapeutic usefulness, the liability for abuse and dependence, and the public health and social harm of each substance. The ECDD advises the Director-General of WHO to reschedule or to amend the scheduling status of a substance. The Director-General will, as appropriate, communicate the recommendations to the Secretary-General of the United Nations, who will in turn communicate the advice to the Commission on Narcotic Drugs. This report summarizes the findings of the forty-third meeting at which the Committee reviewed 11 psychoactive substances: – 5-Methoxy-N,N-diallyltryptamine (5-MeO-DALT) WHO Expert Committee – 3-Fluorophenmetrazine (3-FPM) – 3-Methoxyphencyclidine (3-MeO-PCP) on Drug Dependence – Diphenidine – 2-Methoxydiphenidine (2-MeO-DIPHENIDINE) Forty-third report – Isotonitazene – MDMB-4en-PINACA – CUMYL-PEGACLONE – Flubromazolam – Clonazolam – Diclazepam The report also contains the critical review documents that informed recommendations made by the ECDD regarding international control of those substances. The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for international health matters and public health. One of WHO’s constitutional functions is to provide objective, reliable information and advice in the field of human health, a responsibility that it fulfils in part through its extensive programme of publications. The Organization seeks through its publications to support national health strategies and address the most pressing public health concerns of populations around the world.
    [Show full text]
  • CAS Number Index
    2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5
    [Show full text]
  • Boendedok 2020 Manual För Intervjuformulären
    BoendeDOK 2020 Manual för intervjuformulären Mikael Dahlberg Mats Anderberg Helen Falck Innehållsförteckning Introduktion ___________________________________________________ 4 BoendeDOK __________________________________________________ 6 Inskrivningsintervju __________________________________________ 6 Avstämningsintervju __________________________________________ 7 Utskrivningsintervju __________________________________________ 7 Frågeområden i BoendeDOK ___________________________________ 7 Hantering och förvaring av DOK-material _________________________ 8 Kontaktpersonens roll _________________________________________ 8 Kodning i BoendeDOK ________________________________________ 9 Tidsintervaller ______________________________________________ 10 Frågor om förändring ________________________________________ 10 Att i efterhand ändra intervjusvar _______________________________ 11 Inför intervjun - Klientens samtycke ____________________________ 11 Under intervjun _____________________________________________ 12 Återkoppling av Inskrivningsintervjun ___________________________ 12 BoendeDOK Inskrivningsformulär ________________________________ 16 Intervjuinformation __________________________________________ 16 A. Administrativa uppgifter ___________________________________ 16 B. Bakgrundsinformation _____________________________________ 17 C. Boende _________________________________________________ 17 D. Relationer _______________________________________________ 20 E. Myndighets- och vårdkontakter ______________________________ 21
    [Show full text]
  • 1 'New/Designer Benzodiazepines'
    1 ‘New/Designer Benzodiazepines’: an analysis of the literature and psychonauts’ trip reports 2 Laura Orsolini*1,2,3, John M. Corkery1, Stefania Chiappini1, Amira Guirguis1, Alessandro Vento4,5,6,7, 3 Domenico De Berardis3,8,9, Duccio Papanti1, and Fabrizio Schifano1 4 5 1 Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life and Medical 6 Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK. 7 2 Neomesia Mental Health, Villa Jolanda Hospital, Jesi, Italy. 8 3 Polyedra, Teramo, Italy. 9 4 NESMOS Department (Neurosciences, Mental Health and Sensory Organs), Sapienza University – Rome, School of 10 Medicine and Psychology; Sant’Andrea Hospital, Rome, Italy 11 5 School of psychology - G. Marconi Telematic University, Rome, Italy 12 6 Addictions Observatory (ODDPSS), Rome, Italy 13 7 Mental Health Department - ASL Roma 2, Rome, Italy 14 8 Department of Neuroscience, Imaging and Clinical Science, Chair of Psychiatry, University of “G. D’Annunzio”, Chieti, 15 Italy. 16 9 NHS, Department of Mental Health, Psychiatric Service of Diagnosis and Treatment, Hospital “G. Mazzini”, ASL 4 17 Teramo, Italy. 18 19 Corresponding author: 20 Laura Orsolini, Psychopharmacology, Drug Misuse and Novel Psychoactive Substances Research Unit, School of Life 21 and Medical Sciences, University of Hertfordshire, Hatfield, AL10 9AB, Herts, UK; Villa Jolanda Hospital, Neomesia 22 Mental Health, Villa Jolanda, Italy; Polyedra, Teramo, Italy; E-mail address: [email protected]. Tel.: (+39) 392 23 3244643. 24 25 Conflicts of Interest 26 The authors declare that this research was conducted in the absence of any commercial or financial relationships 27 that could be construed as a potential conflict of interest.
    [Show full text]
  • Förordning Om Ändring I Förordningen (1992:1554) Om Kontroll Av Narkotika;
    Príloha 11 k rozhodnutiu švédskych úradov vlády 22. februára 2018 § 79 1. ------IND- 2018 0079 S-- SK- ------ 20180302 --- --- PROJET Zbierka zákonov Švédska SFS Published on issued on 1 March 2018. The government hereby lays down1 that Annex 1 to the Ordinance (1992:1554) on the control of narcotic drugs2 shall read as set out below. This ordinance shall enter into force on 10 April 2018. On behalf of the Government ANNIKA STRANDHÄLL Lars Hedengran (Ministry of Health and Social Affairs) 1 See Directive (EU) 2015/1535 of the European Parliament and of the Council of 9 September 2015 laying down a procedure for the provision of information in the field of technical regulations and of rules on Information Society services. 2 Ordinance reprinted as 1993:784. 1 SFS Annex 13 List of substances to be considered narcotic drugs according to the Narcotic Drugs Punishments Act Stimulants of the central nervous system ethylamphetamine (2-ethylamino-1-phenylpropane) fenethylline [1-phenyl-1-piperidyl-(2)-methyl]acetate 1-phenyl-2-butylamine N-hydroxyamphetamine propylhexedrine 4-methylthioamphetamine (4-MTA) modafinil 4-methoxy-N-methylamphetamine (PMMA, 4-MMA) 2,5-dimethoxy-4-ethylthiophenethylamine (2C-T-2) 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) 4-iodo-2,5-dimethoxyphenethylamine (2C-I) 2,4,5-trimethoxyamphetamine (TMA-2) 4-methylmethcathinone (mephedrone) 4-fluoramphetamine 1-(4-methoxyphenyl)-2-(methylamino)propan-1-one (methedrone) 1-(1,3-benzodioxol-5-yl)-2-pyrrolidin-1-yl-pentan-1-one (MDPV) 1-(1,3-benzodioxol-5-yl)-2-(methylamino)butan-1-one
    [Show full text]
  • Bioanalytical Studies of Designer Benzodiazepines
    From DEPARTMENT OF LABORATORY MEDICINE Karolinska Institutet, Stockholm, Sweden BIOANALYTICAL STUDIES OF DESIGNER BENZODIAZEPINES Madeleine Pettersson Bergstrand Stockholm 2018 All previously published papers were reproduced with permission from the publisher. Published by Karolinska Institutet. Printed by Eprint AB © Madeleine Pettersson Bergstrand, 2018 ISBN 978-91-7831-063-0 Front page illustration: Sandra Eriksson Bioanalytical studies of designer benzodiazepines THESIS FOR DOCTORAL DEGREE (Ph.D.) The thesis will be defended at 4X, Alfred Nobels allé 8, Huddinge Friday, May 25, 2018 at 09.00 a.m. By Madeleine Pettersson Bergstrand Principal Supervisor: Opponent: Prof. Anders Helander Ass. Prof. Elisabeth Leere Øiestad Karolinska Institutet Oslo University Hospital Department of Laboratory Medicine Department of Forensic Sciences Division of Clinical Chemistry Clinic for Laboratory medicine Co-supervisor: Examination Board: Prof. Olof Beck Prof. Åsa Emmer Karolinska Institutet KTH Royal Institute of Technology Department of Laboratory Medicine Department of Chemistry Division of Clinical Pharmacology Division of Applied Physical Chemistry Docent Stefan Borg Karolinska Institutet Department of Clinical Neuroscience Docent Pierre Lafolie Karolinska Institutet Department of Medicine Division of Clinical Epidemiology ABSTRACT The fast appearance of benzodiazepine analogues, referred to as new psychoactive substance (NPS) or designer benzodiazepines, requires the continuous update of detection methods in order to keep up with the latest drugs on the recreational drug market. Moreover, as usually only limited information on toxicity and excretion patterns of these new drugs exists, this needs to be evaluated to report on adverse effects and to determine suitable targets for drug testing. Urine drug testing usually involves screening using immunoassay followed by confirmation of positive screening results using mass spectrometric (MS) methods.
    [Show full text]
  • Current Awareness in Clinical Toxicology Editors: Damian Ballam Msc and Allister Vale MD
    Current Awareness in Clinical Toxicology Editors: Damian Ballam MSc and Allister Vale MD May 2016 CONTENTS General Toxicology 8 Metals 33 Management 16 Pesticides 35 Drugs 19 Chemical Warfare 37 Chemical Incidents & 28 Plants 37 Pollution Chemicals 29 Animals 38 CURRENT AWARENESS PAPERS OF THE MONTH Efficacy and effectiveness of anti-digoxin antibodies in chronic digoxin poisonings from the DORA study (ATOM-1) Chan BS, Isbister GK, O'Leary M, Chiew A, Buckley NA. Clin Toxicol 2016; online early: doi: 10.1080/15563650.2016.1175620: Context We hypothesized that in chronic digoxin toxicity, anti-digoxin antibodies (Fab) would be efficacious in binding digoxin, but this may not translate into improved clinical outcomes. Objective This study aims to investigate changes in free digoxin concentrations and clinical effects on heart rate and potassium concentrations in chronic digoxin poisoning when anti-digoxin Fab are given. Materials and methods This is a prospective observational study. Patients were recruited if they have been treated with anti-digoxin Fab for chronic digoxin poisoning. Data was entered into a standardised prospective form, supplemented with medical records. Their serum or plasma was collected, analysed for free and bound digoxin and free anti-digoxin Fab concentrations. Results From September 2013 to February 2015, 36 patients (median age, 78 years; 22 females) Current Awareness in Clinical Toxicology is produced monthly for the American Academy of Clinical Toxicology by the Birmingham Unit of the UK National Poisons Information Service, with contributions from the Cardiff, Edinburgh, and Newcastle Units. The NPIS is commissioned by Public Health England 2 were recruited from 18 hospitals.
    [Show full text]
  • A Review of the Evidence of Use and Harms of Novel Benzodiazepines
    ACMD Advisory Council on the Misuse of Drugs Novel Benzodiazepines A review of the evidence of use and harms of Novel Benzodiazepines April 2020 1 Contents 1. Introduction ................................................................................................................................. 4 2. Legal control of benzodiazepines .......................................................................................... 4 3. Benzodiazepine chemistry and pharmacology .................................................................. 6 4. Benzodiazepine misuse............................................................................................................ 7 Benzodiazepine use with opioids ................................................................................................... 9 Social harms of benzodiazepine use .......................................................................................... 10 Suicide ............................................................................................................................................. 11 5. Prevalence and harm summaries of Novel Benzodiazepines ...................................... 11 1. Flualprazolam ......................................................................................................................... 11 2. Norfludiazepam ....................................................................................................................... 13 3. Flunitrazolam ..........................................................................................................................
    [Show full text]
  • Toxicology Reference Material
    toxicology Toxicology covers a wide range of disciplines, including therapeutic drug monitoring, clinical toxicology, forensic toxicology (drug driving, criminal and coroners), drugs in sport and work place drug testing, as well as academia and research. Those working in the field have a professional interest in the detection and measurement of alcohol, drugs, poisons and their breakdown products in biological samples, together with the interpretation of these measurements. Abuse and misuse of drugs is one of the biggest problems facing our society today. Acute poisoning remains one of the commonest medical emergencies, accounting for 10-20% of hospital admissions for general medicine [Dargan & Jones, 2001]. Many offenders charged with violent crimes, or victims of violent crime may have been under the influence of drugs at the time the act was committed. The use of mind-altering drugs in the work place, or whilst in control of a motor vehicle places others in danger [Drummer, 2001]. Performance enhancing drugs in sport make for an uneven playing field and distract from the core ethic of sportsmanship. Patterns of drug abuse around the world are constantly evolving. They vary between geographies; from one country to another and even from region to region or population to population within countries. With a European presence, a wide reaching network of global customers and distributors, and activate participation in relevant professional societies, Chiron is well positioned to develop and deliver relevant, and current standards to meet customer demand in this challenging field. Chiron AS Stiklestadvn. 1 N-7041 Trondheim Norway Phone No.: +47 73 87 44 90 Fax No.: +47 73 87 44 99 E-mail: [email protected] Website: www.chiron.no Org.
    [Show full text]
  • Infographics About Synthetic Opioids
    UNODC LEADING THE INTERGRATED GLOBAL RESPONSE TO THE OPIOID CRISIS P I L L A R 1 P I L L A R 2 P I L L A R 3 P I L L A R 4 P I L L A R 5 I N T E R N A T I O N A L L A W S T R E N G T H E N I N G C O U N T E R E A R L Y W A R N I N G A N D R A T I O N A L P R E S C R I B I N G A N D S T R E N G T H E N I N G A N D S U P P O R T I N G E N F O R C E M E N T O P E R A T I O N S N A R C O T I C C A P A C I T Y A N D T R E N D A N A L Y S I S A C C E S S T O O P I O I D S P R E V E N T I O N A N D T R E A T M E N T T O D I S R U P T T R A F F I C K I N G I N T E R N A T I O N A L C O O P E R A T I O N IDENTIFYING THE MOST PREVELANT, PERSISTANT AND HARMFUL SYNTHETIC OPIOIDS U N O D C 282 90 E A R L Y TOXICOLOGY COLLABORATING IN COUNTRIES W A R N I N G INFORMED THREATS LABORATORIES A D V I S O R Y ASSESSMENTS PHARMACOLOGICAL INFORMATION L A B O R A T O R I E S A N D D A T A P O I N T S L A B O R A T O R I E S D A T A P O I N T S G L O B A L S M A R T U P D A T E S 21,400+ 120 DATA POINTS FROM COUNTRIES SYNTHETIC SEDATIVE 74 OPIOIDS HYPNOTICS REPORTED MIRRORING TO UNODC SYNTHETIC E A R L Y OPIOID TRENDS W A R N I N G A D V I S O R Y B Y 2019 131% IN THE LAST * * 3 Y E A R S Note: * 2019 data collection not finalized LIST OF SYNTHETIC OPIOIDS REPORTED TO THE UNODC EWA FROM 2009-2019 S C H E D U L E D 2-Fluorofentanyl Furanylfentanyl 4-Fluorobutyrfentanyl Methoxyacetylfentanyl 4-Fluoroisobutyrfentanyl MT-45 S C H E D U L E I Acrylfentanyl Ocfentanil ( 1 9 6 1 ) AH-7921 Tetrahydrofuranylfentanyl Butyrfentanyl U-47700 S C H E D U L E I & I V Cyclopropylfentanyl
    [Show full text]
  • Volatiles and Inhalants Screens
    Phone: 303-440-4500 www.chematox.com Postmortem Toxicology Test Codes [email protected] Utilize the following test codes on your request for analysis. Please contact us if you are interested in testing for a compound not listed here, if you need guidance in selecting the appropriate testing for your case, or if you have any other questions or concerns. A “reflex test” is additional testing added as a result of a positive result on original testing. Volatiles and Inhalants 70001 Volatiles: Ethanol, Acetone, Isopropanol and Methanol (Positive results reflex to 70002) 70002 Volatiles: Reflex Test on alternative specimen (Vitreous or Urine) 70003 Inhalants: Difluoroethane and polyfluorinated ethanes (DFE/PFE) and Toluene 70005 Carbon Monoxide Screens For all screening panels and tests, positive results will reflex to targeted confirmation testing. Screening Panels 70010 Drugs of Abuse Panel – Limited Benzodiazepines [70015] Cocaine Metabolite [70020] Methamphetamine/MDMA [70025] Opiates [70026] Zolpidem [70031] 70011 Drugs of Abuse Panel – Standard Benzodiazepines [70015] Cannabinoids [70017] Cocaine Metabolite [70020] Methamphetamine/MDMA [70025] Opiates [70026] Oxycodone [70027] Zolpidem [70031] 70012 Drugs of Abuse Panel – Expanded Barbiturates [70014] Benzodiazepines [70015] Cannabinoids [70017] Carisoprodol [70018] 1 Phone: 303-440-4500 www.chematox.com Postmortem Toxicology Test Codes [email protected] Cocaine Metabolite [70020] Fentanyl [70021] Methamphetamine/MDMA [70025] Opiates [70026] Oxycodone [70027] Tramadol [70028] Zolpidem
    [Show full text]
  • LJMU Research Online
    LJMU Research Online Dowling, G, Kavanagh, PV, Eckhardt, HG, Twamley, B, Hessman, G, McLaughlin, G, O’ Brien, J and Brandt, SD An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: the microscale syntheses of nitrazolam and clonazolam, for use as reference materials, utilizing polymer supported reagents http://researchonline.ljmu.ac.uk/id/eprint/8261/ Article Citation (please note it is advisable to refer to the publisher’s version if you intend to cite from this work) Dowling, G, Kavanagh, PV, Eckhardt, HG, Twamley, B, Hessman, G, McLaughlin, G, O’ Brien, J and Brandt, SD (2018) An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: the microscale LJMU has developed LJMU Research Online for users to access the research output of the University more effectively. Copyright © and Moral Rights for the papers on this site are retained by the individual authors and/or other copyright owners. Users may download and/or print one copy of any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. You may not engage in further distribution of the material or use it for any profit-making activities or any commercial gain. The version presented here may differ from the published version or from the version of the record. Please see the repository URL above for details on accessing the published version and note that access may require a subscription. For more information please contact [email protected] http://researchonline.ljmu.ac.uk/ http://researchonline.ljmu.ac.uk/ Accepted/uncorrected version – Drug Testing and Analysis (08 March 2018) An approach to shortening the timeframe between the emergence of new compounds on the drugs market and the availability of reference standards: the microscale syntheses of nitrazolam and clonazolam, for use as reference materials, utilizing polymer supported reagents a,b, b c Geraldine Dowling *, Pierce V.
    [Show full text]